In 2023, the FDA and CDC's Advisory Committee on Immunization Practices (ACIP) voted in favor of recommending the monoclonal antibody nirsevimab (Beyfortus) for protecting a wide swath of at-risk infants from RSV. The second RSV monoclonal antibody clesrovimab (Enflonsia) received FDA approval in 2025.

Here are five things parents and caregivers should know about the new vaccination schedule changes for children. The new guidelines no longer universally recommend children receive vaccines for rotavirus, hepatitis A and hepatitis B, meningitis (meningococcal disease), RSV (respiratory syncytial virus), COVID, and influenza (the flu).

Respiratory syncytial virus (RSV) is a common virus that affects the nose, throat, and lungs. For most healthy adults and children, it causes only mild, cold-like symptoms and goes away on its own. Infants under 6 months of age,

As the number of RSV infections rises, two recent studies found that protecting babies against the disease prevented hospitalizations. The post Studies find RSV protection for infants cuts hospitalizations appeared first on Straight Arrow News.

We’re still in the early stages of RSV season, but doctors are already worried about a rise in cases. As we head into the peak of 2025 RSV season, parents are once again facing an uptick in cases, with health experts warning that the virus could affect ...

Scientists have uncovered strong evidence that infection with RSV in the first months of life can significantly raise the risk of developing childhood asthma, especially in children with a family history of allergies.

How effective is nirsevimab at preventing respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD), hospitalizations related to RSV, and any RSV infection?

PHILADELPHIA (WPVI) -- A host of viruses go around every winter, but RSV is one that causes a lot of concern for the parents of very young children. Coughing, sneezing and kids blowing noses, it's the sound of winter. But the culprit behind it could be RSV ...